# US 11,026,970 B2 · Methods and treatment of trauma adverse events with oxygen reduced blood > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,026,970 B2 - Document ID: US11026970B2 - Status: Granted - Kind: B2 - Application number: 16/614,683 - Filed: 2018-05-18 - Published: 2020-06-11 - Granted: 2021-06-08 - Earliest claimed: 2017-05-19 - Assignees: Hemanext Inc. - Applicants: Hemanext Inc. - Inventors: Andrew Dunham; Tatsuro Yoshida - Web page: https://patentgrep.com/patent/US11026970B2 ## CPC - A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives - A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure - A61P 11/00: Drugs for disorders of the respiratory system - A61P 13/12: of the kidneys - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions. ## Claims ### Claim 1 A method of reducing the risk of organ damage in a hemorrhagic trauma adverse event in a hemorrhagic trauma subject in need thereof comprising administering stored oxygen reduced blood to a subject having hemorrhagic trauma, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level compared to an oxygen saturation level prior to storage for a storage period, wherein said risk of organ damage is reduced relative to a patient receiving conventionally stored blood. ### Claim 2 (depends on 1) The method of claim 1, wherein said organ damage is selected from the group consisting of liver injury, lung failure, kidney failure, and heart failure. ### Claim 3 (depends on 1) The method of claim 1, wherein said hemorrhagic trauma subject in need thereof has increased levels of aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), or both increased AST and ALT prior to said administering. ### Claim 4 (depends on 1) The method of claim 1, wherein said trauma subject in need thereof has a glucose level of greater than 200 mg/dL prior to said administering. ### Claim 5 (depends on 1) The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises an increased lactate level prior to said administering. ### Claim 6 (depends on 1) The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises increased urine neutrophil gelatinase-associated lipocalin (u-NGAL) prior to said administering. ### Claim 7 (depends on 1) The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises increased serum creatinine prior to said administering. ### Claim 8 (depends on 1) The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises increased blood urea nitrogen (BUN) prior to said administering. ### Claim 9 (depends on 1) The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises decreased hematocrit prior to said administering. ### Claim 10 (depends on 1) The method of claim 1, wherein said stored oxygen reduced blood is depleted to an oxygen saturation of 20% or less prior to said storage period. ### Claim 11 (depends on 1) The method of claim 1, wherein said stored oxygen reduced blood comprises an oxygen saturation of 20% or less during said storage period. ### Claim 12 (depends on 1) The method of claim 1, wherein said stored oxygen reduced blood is also carbon dioxide reduced. ### Claim 13 (depends on 1) The method of claim 1, wherein said storage period is up to 42 days. ### Claim 14 (depends on 3) The method of claim 3, wherein said increased AST, ALT, or both increased AST and ALT level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood. ### Claim 15 (depends on 4) The method of claim 4, wherein said glucose level is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood. ### Claim 16 (depends on 5) The method of claim 5, wherein said increased lactate level is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood. ### Claim 17 (depends on 6) The method of claim 6, wherein said increased urine neutrophil gelatinase-associated lipocalin (u-NGAL) is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood. ### Claim 18 (depends on 7) The method of claim 7, wherein said increased serum creatinine is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood. ### Claim 19 (depends on 8) The method of claim 8, wherein said increased blood urea nitrogen (BUN) is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood. ### Claim 20 (depends on 9) The method of claim 9, wherein said decreased hematocrit is increased after said administering relative to a patient receiving conventionally stored blood.